Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times
Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dial...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-10, Vol.16 (10), p.e0257646-e0257646 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0257646 |
|---|---|
| container_issue | 10 |
| container_start_page | e0257646 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Bachelet, Thomas Bourdenx, Jean-Philippe Martinez, Charlie Mucha, Simon Martin-Dupont, Philippe Perier, Valerie Pommereau, Antoine |
| description | Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dialysis patients including 193 who underwent anti-Spike-Protein-Receptor-Binding-Domain (RBD) IgG analysis. We show that a pro-active vaccine campaign is effective in convincing most patients to be vaccinated (95%) and frequently elicits a specific antibody response (94.3% after two doses and 98.4% after three doses). Only immunocompromised Status is associated with lack of seroconversion (OR 7.6 [1.5–38.2], p = 0.02). We also identify factors associated with low response (last quartile; IgG7000AU/mL): age; previous SARS-CoV-2 infection and active Cancer. From this experience, we propose a strategy integrating anti-spike IgG monitoring to guide revaccination and dialysis center management in pandemic times. |
| doi_str_mv | 10.1371/journal.pone.0257646 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2579349974</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A677999440</galeid><doaj_id>oai_doaj_org_article_4cdb15984f3c4698aa59fa7964d8bd81</doaj_id><sourcerecordid>A677999440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c735t-289915a4d18051282aa3f8bc36b46de34db421e0403df701244fd0fda92ace4c3</originalsourceid><addsrcrecordid>eNqNk9tu1DAQhiMEomXhDZCwhITgIkscOwf3Amkph65UUbQLvbUmtpO6JPZiOxV9Lx4Q7wHYRb1AuUg8-eYfz29PkjzF2RSTCr--tqMz0E9X1qhplhdVSct7yTFmJE_LPCP3976PkkfeX2dZQeqyfJgcEVriLCP4OPl5Ng7WQY-c8lHJKwRtUA4tZ4tlemov0xwNi08zdANCaKM80gZJDf2t1x6tIGhlgj9BcxNU5-LSdAhM0Ole_nKlv6n0s7NBaZMu3r7bEI2Vt2iwRgfr1lnBogEMdOqvvIjaym1KrsBINWiBgh6Uf5w8aKH36snuPUm-fnj_5fQsPb_4OD-dnaeiIkVI85oxXACVuM4KnNc5AGnrRpCyoaVUhMqG5lhlNCOyrTKcU9rKrJXAchCKCjJJnm11V731fGe459FrRihjFY3EfEtIC9d85fQA7pZb0HwTsK7j4IIWveJUyAYXrKYtEbRkNUDBWqhYSWXdyBpHrTe7amMzKLnuPh7MgejhH6OveGdveE0ZrlkdBV7uBJz9Piof-KC9UH0PRtlxu-8yL1lOIvr8H_Tu7nZUB7EBbVob64q1KJ-VVcUYo9G7STK9g4rP5sTi7Wx1jB8kvDpIiExQP0IHo_d8vlz8P3txeci-2GOvFPThytt-DDpe7EOQbkHhrPdOtX9MxhlfD9dvN_h6uPhuuMgv8CMW1w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579349974</pqid></control><display><type>article</type><title>Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Bachelet, Thomas ; Bourdenx, Jean-Philippe ; Martinez, Charlie ; Mucha, Simon ; Martin-Dupont, Philippe ; Perier, Valerie ; Pommereau, Antoine</creator><contributor>Ito, Etsuro</contributor><creatorcontrib>Bachelet, Thomas ; Bourdenx, Jean-Philippe ; Martinez, Charlie ; Mucha, Simon ; Martin-Dupont, Philippe ; Perier, Valerie ; Pommereau, Antoine ; Ito, Etsuro</creatorcontrib><description>Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dialysis patients including 193 who underwent anti-Spike-Protein-Receptor-Binding-Domain (RBD) IgG analysis. We show that a pro-active vaccine campaign is effective in convincing most patients to be vaccinated (95%) and frequently elicits a specific antibody response (94.3% after two doses and 98.4% after three doses). Only immunocompromised Status is associated with lack of seroconversion (OR 7.6 [1.5–38.2], p = 0.02). We also identify factors associated with low response (last quartile; IgG<500AU/mL): immunocompromised status, age, absence of RAAS inhibitors, low lymphocytes count, high C Reactive Protein; and with high response (high quartile; IgG>7000AU/mL): age; previous SARS-CoV-2 infection and active Cancer. From this experience, we propose a strategy integrating anti-spike IgG monitoring to guide revaccination and dialysis center management in pandemic times.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0257646</identifier><identifier>PMID: 34610031</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Antibodies ; Antibody response ; Antigens ; Biology and life sciences ; C-reactive protein ; Care and treatment ; Complications and side effects ; COVID-19 ; Data collection ; Dialysis ; Drug dosages ; Health risks ; Hemodialysis ; Hemodialysis patients ; Immune response ; Immune response (humoral) ; Immune system ; Immunoglobulin G ; Infections ; Kidney diseases ; Lymphocytes ; Medicine and health sciences ; Monitoring ; mRNA ; mRNA vaccines ; Multivariate analysis ; Pandemics ; Patients ; Proteins ; Risk factors ; Seroconversion ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Telemedicine ; Transplants & implants ; Vaccines ; Viral diseases</subject><ispartof>PloS one, 2021-10, Vol.16 (10), p.e0257646-e0257646</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 BACHELET et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 BACHELET et al 2021 BACHELET et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c735t-289915a4d18051282aa3f8bc36b46de34db421e0403df701244fd0fda92ace4c3</citedby><cites>FETCH-LOGICAL-c735t-289915a4d18051282aa3f8bc36b46de34db421e0403df701244fd0fda92ace4c3</cites><orcidid>0000-0002-3273-1444</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491898/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491898/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2095,2914,23846,27903,27904,53769,53771,79346,79347</link.rule.ids></links><search><contributor>Ito, Etsuro</contributor><creatorcontrib>Bachelet, Thomas</creatorcontrib><creatorcontrib>Bourdenx, Jean-Philippe</creatorcontrib><creatorcontrib>Martinez, Charlie</creatorcontrib><creatorcontrib>Mucha, Simon</creatorcontrib><creatorcontrib>Martin-Dupont, Philippe</creatorcontrib><creatorcontrib>Perier, Valerie</creatorcontrib><creatorcontrib>Pommereau, Antoine</creatorcontrib><title>Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times</title><title>PloS one</title><description>Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dialysis patients including 193 who underwent anti-Spike-Protein-Receptor-Binding-Domain (RBD) IgG analysis. We show that a pro-active vaccine campaign is effective in convincing most patients to be vaccinated (95%) and frequently elicits a specific antibody response (94.3% after two doses and 98.4% after three doses). Only immunocompromised Status is associated with lack of seroconversion (OR 7.6 [1.5–38.2], p = 0.02). We also identify factors associated with low response (last quartile; IgG<500AU/mL): immunocompromised status, age, absence of RAAS inhibitors, low lymphocytes count, high C Reactive Protein; and with high response (high quartile; IgG>7000AU/mL): age; previous SARS-CoV-2 infection and active Cancer. From this experience, we propose a strategy integrating anti-spike IgG monitoring to guide revaccination and dialysis center management in pandemic times.</description><subject>Antibodies</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Biology and life sciences</subject><subject>C-reactive protein</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>COVID-19</subject><subject>Data collection</subject><subject>Dialysis</subject><subject>Drug dosages</subject><subject>Health risks</subject><subject>Hemodialysis</subject><subject>Hemodialysis patients</subject><subject>Immune response</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>Immunoglobulin G</subject><subject>Infections</subject><subject>Kidney diseases</subject><subject>Lymphocytes</subject><subject>Medicine and health sciences</subject><subject>Monitoring</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Multivariate analysis</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Proteins</subject><subject>Risk factors</subject><subject>Seroconversion</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Telemedicine</subject><subject>Transplants & implants</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tu1DAQhiMEomXhDZCwhITgIkscOwf3Amkph65UUbQLvbUmtpO6JPZiOxV9Lx4Q7wHYRb1AuUg8-eYfz29PkjzF2RSTCr--tqMz0E9X1qhplhdVSct7yTFmJE_LPCP3976PkkfeX2dZQeqyfJgcEVriLCP4OPl5Ng7WQY-c8lHJKwRtUA4tZ4tlemov0xwNi08zdANCaKM80gZJDf2t1x6tIGhlgj9BcxNU5-LSdAhM0Ole_nKlv6n0s7NBaZMu3r7bEI2Vt2iwRgfr1lnBogEMdOqvvIjaym1KrsBINWiBgh6Uf5w8aKH36snuPUm-fnj_5fQsPb_4OD-dnaeiIkVI85oxXACVuM4KnNc5AGnrRpCyoaVUhMqG5lhlNCOyrTKcU9rKrJXAchCKCjJJnm11V731fGe459FrRihjFY3EfEtIC9d85fQA7pZb0HwTsK7j4IIWveJUyAYXrKYtEbRkNUDBWqhYSWXdyBpHrTe7amMzKLnuPh7MgejhH6OveGdveE0ZrlkdBV7uBJz9Piof-KC9UH0PRtlxu-8yL1lOIvr8H_Tu7nZUB7EBbVob64q1KJ-VVcUYo9G7STK9g4rP5sTi7Wx1jB8kvDpIiExQP0IHo_d8vlz8P3txeci-2GOvFPThytt-DDpe7EOQbkHhrPdOtX9MxhlfD9dvN_h6uPhuuMgv8CMW1w</recordid><startdate>20211005</startdate><enddate>20211005</enddate><creator>Bachelet, Thomas</creator><creator>Bourdenx, Jean-Philippe</creator><creator>Martinez, Charlie</creator><creator>Mucha, Simon</creator><creator>Martin-Dupont, Philippe</creator><creator>Perier, Valerie</creator><creator>Pommereau, Antoine</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3273-1444</orcidid></search><sort><creationdate>20211005</creationdate><title>Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times</title><author>Bachelet, Thomas ; Bourdenx, Jean-Philippe ; Martinez, Charlie ; Mucha, Simon ; Martin-Dupont, Philippe ; Perier, Valerie ; Pommereau, Antoine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c735t-289915a4d18051282aa3f8bc36b46de34db421e0403df701244fd0fda92ace4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Biology and life sciences</topic><topic>C-reactive protein</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>COVID-19</topic><topic>Data collection</topic><topic>Dialysis</topic><topic>Drug dosages</topic><topic>Health risks</topic><topic>Hemodialysis</topic><topic>Hemodialysis patients</topic><topic>Immune response</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>Immunoglobulin G</topic><topic>Infections</topic><topic>Kidney diseases</topic><topic>Lymphocytes</topic><topic>Medicine and health sciences</topic><topic>Monitoring</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Multivariate analysis</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Proteins</topic><topic>Risk factors</topic><topic>Seroconversion</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Telemedicine</topic><topic>Transplants & implants</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bachelet, Thomas</creatorcontrib><creatorcontrib>Bourdenx, Jean-Philippe</creatorcontrib><creatorcontrib>Martinez, Charlie</creatorcontrib><creatorcontrib>Mucha, Simon</creatorcontrib><creatorcontrib>Martin-Dupont, Philippe</creatorcontrib><creatorcontrib>Perier, Valerie</creatorcontrib><creatorcontrib>Pommereau, Antoine</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bachelet, Thomas</au><au>Bourdenx, Jean-Philippe</au><au>Martinez, Charlie</au><au>Mucha, Simon</au><au>Martin-Dupont, Philippe</au><au>Perier, Valerie</au><au>Pommereau, Antoine</au><au>Ito, Etsuro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times</atitle><jtitle>PloS one</jtitle><date>2021-10-05</date><risdate>2021</risdate><volume>16</volume><issue>10</issue><spage>e0257646</spage><epage>e0257646</epage><pages>e0257646-e0257646</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Dialysis patients are both the most likely to benefit from vaccine protection against SARS-CoV-2 and at the highest risk of not developing an immune response. Data from the medical field are thus mandatory. We report our experience with a BNT162b2-mRNA vaccine in a retrospective analysis of 241 dialysis patients including 193 who underwent anti-Spike-Protein-Receptor-Binding-Domain (RBD) IgG analysis. We show that a pro-active vaccine campaign is effective in convincing most patients to be vaccinated (95%) and frequently elicits a specific antibody response (94.3% after two doses and 98.4% after three doses). Only immunocompromised Status is associated with lack of seroconversion (OR 7.6 [1.5–38.2], p = 0.02). We also identify factors associated with low response (last quartile; IgG<500AU/mL): immunocompromised status, age, absence of RAAS inhibitors, low lymphocytes count, high C Reactive Protein; and with high response (high quartile; IgG>7000AU/mL): age; previous SARS-CoV-2 infection and active Cancer. From this experience, we propose a strategy integrating anti-spike IgG monitoring to guide revaccination and dialysis center management in pandemic times.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>34610031</pmid><doi>10.1371/journal.pone.0257646</doi><tpages>e0257646</tpages><orcidid>https://orcid.org/0000-0002-3273-1444</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-10, Vol.16 (10), p.e0257646-e0257646 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2579349974 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Antibodies Antibody response Antigens Biology and life sciences C-reactive protein Care and treatment Complications and side effects COVID-19 Data collection Dialysis Drug dosages Health risks Hemodialysis Hemodialysis patients Immune response Immune response (humoral) Immune system Immunoglobulin G Infections Kidney diseases Lymphocytes Medicine and health sciences Monitoring mRNA mRNA vaccines Multivariate analysis Pandemics Patients Proteins Risk factors Seroconversion Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Telemedicine Transplants & implants Vaccines Viral diseases |
| title | Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T13%3A16%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Humoral%20response%20after%20SARS-CoV-2%20mRNA%20vaccines%20in%20dialysis%20patients:%20Integrating%20anti-SARS-CoV-2%20Spike-Protein-RBD%20antibody%20monitoring%20to%20manage%20dialysis%20centers%20in%20pandemic%20times&rft.jtitle=PloS%20one&rft.au=Bachelet,%20Thomas&rft.date=2021-10-05&rft.volume=16&rft.issue=10&rft.spage=e0257646&rft.epage=e0257646&rft.pages=e0257646-e0257646&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0257646&rft_dat=%3Cgale_plos_%3EA677999440%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579349974&rft_id=info:pmid/34610031&rft_galeid=A677999440&rft_doaj_id=oai_doaj_org_article_4cdb15984f3c4698aa59fa7964d8bd81&rfr_iscdi=true |